

# Josã© das Neves

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3504931/publications.pdf>

Version: 2024-02-01

235  
papers

88,211  
citations

9234

74  
h-index

1250

226  
g-index

280  
all docs

280  
docs citations

280  
times ranked

108583  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
2	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	6.3	7,664
3	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	6.3	5,578
4	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	6.3	5,298
5	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
6	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	6.3	4,934
7	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. <i>JAMA Oncology</i> , 2017, 3, 524.	3.4	4,254
8	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	6.3	4,203
9	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	6.3	3,928
10	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	6.3	3,565
11	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
12	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
13	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	6.3	2,005
14	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	6.3	1,879
15	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	3.4	1,691
16	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	6.3	1,612
17	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	6.3	1,589
18	Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. <i>Drug Discovery Today</i> , 2007, 12, 1068-1075.	3.2	1,262

#	ARTICLE	IF	CITATIONS
19	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553.	3.4	1,260
20	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
21	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	6.3	740
22	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. <i>JAMA Oncology</i> , 2022, 8, 420.	3.4	719
23	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
24	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
25	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	6.3	573
26	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
27	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
28	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV,the</i> , 2016, 3, e361-e387.	2.1	461
29	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
30	Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review. <i>Progress in Polymer Science</i> , 2014, 39, 2030-2075.	11.8	382
31	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV,the</i> , 2019, 6, e831-e859.	2.1	341
32	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
33	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	6.3	335
34	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
35	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	6.3	284
36	Amorphous solid dispersions: Rational selection of a manufacturing process. <i>Advanced Drug Delivery Reviews</i> , 2016, 100, 85-101.	6.6	279

#	ARTICLE	IF	CITATIONS
37	Oral Bioavailability of Insulin Contained in Polysaccharide Nanoparticles. <i>Biomacromolecules</i> , 2007, 8, 3054-3060.	2.6	236
38	Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 83, 427-435.	2.0	225
39	Development and characterization of new insulin containing polysaccharide nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2006, 53, 193-202.	2.5	212
40	Gels as vaginal drug delivery systems. <i>International Journal of Pharmaceutics</i> , 2006, 318, 1-14.	2.6	210
41	Polymer-based nanoparticles for oral insulin delivery: Revisited approaches. <i>Biotechnology Advances</i> , 2015, 33, 1342-1354.	6.0	189
42	Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1816-1827.	6.6	187
43	Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 458-477.	6.6	179
44	Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications. <i>Advanced Healthcare Materials</i> , 2018, 7, 1701035.	3.9	173
45	Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. <i>Journal of Controlled Release</i> , 2016, 232, 29-41.	4.8	168
46	Towards the characterization of an in vitro triple co-culture intestine cell model for permeability studies. <i>International Journal of Pharmaceutics</i> , 2013, 458, 128-134.	2.6	157
47	Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. <i>Drug Delivery and Translational Research</i> , 2011, 1, 299-308.	3.0	150
48	On the issue of transparency and reproducibility in nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 629-635.	15.6	149
49	Oral insulin delivery by means of solid lipid nanoparticles. <i>International Journal of Nanomedicine</i> , 2007, 2, 743-9.	3.3	149
50	Development and Comparison of Different Nanoparticulate Polyelectrolyte Complexes as Insulin Carriers. <i>International Journal of Peptide Research and Therapeutics</i> , 2006, 12, 131-138.	0.9	144
51	Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 1085-1104.	2.4	131
52	The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. <i>Biomaterials</i> , 2014, 35, 9199-9207.	5.7	127
53	Insulin-loaded alginate microspheres for oral delivery – Effect of polysaccharide reinforcement on physicochemical properties and release profile. <i>Carbohydrate Polymers</i> , 2007, 69, 725-731.	5.1	126
54	Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B Coculture Models To Predict Intestinal and Colonic Permeability Compared to Caco-2 Monoculture. <i>Molecular Pharmaceutics</i> , 2017, 14, 1264-1270.	2.3	123

#	ARTICLE	IF	CITATIONS
55	Advances in biomaterials for preventing tissue adhesion. <i>Journal of Controlled Release</i> , 2017, 261, 318-336.	4.8	115
56	Chitosan-based nanoparticles for rosmarinic acid ocular delivery—In vitro tests. <i>International Journal of Biological Macromolecules</i> , 2016, 84, 112-120.	3.6	114
57	Cell-based <i>in vitro</i> models for predicting drug permeability. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 607-621.	1.5	113
58	The progress of essential oils as potential therapeutic agents: a review. <i>Journal of Essential Oil Research</i> , 2020, 32, 279-295.	1.3	110
59	Facilitated nanoscale delivery of insulin across intestinal membrane models. <i>International Journal of Pharmaceutics</i> , 2011, 412, 123-131.	2.6	107
60	Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. <i>Biomaterials</i> , 2014, 35, 7172-7179.	5.7	105
61	Mannose-functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 114, 103-113.	1.9	104
62	Polymer-based nanocarriers for vaginal drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2015, 92, 53-70.	6.6	102
63	Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis. <i>International Journal of Pharmaceutics</i> , 2018, 536, 478-485.	2.6	101
64	Microfluidic Assembly of a Multifunctional Tailorable Composite System Designed for Site Specific Combined Oral Delivery of Peptide Drugs. <i>ACS Nano</i> , 2015, 9, 8291-8302.	7.3	96
65	Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. <i>Carbohydrate Polymers</i> , 2011, 84, 919-925.	5.1	95
66	Thiolation and Cell-Penetrating Peptide Surface Functionalization of Porous Silicon Nanoparticles for Oral Delivery of Insulin. <i>Advanced Functional Materials</i> , 2016, 26, 3405-3416.	7.8	94
67	The solid progress of nanomedicine. <i>Drug Delivery and Translational Research</i> , 2020, 10, 726-729.	3.0	91
68	Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. <i>Biomedical Chromatography</i> , 2006, 20, 898-903.	0.8	90
69	Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs. <i>Journal of Controlled Release</i> , 2016, 243, 43-53.	4.8	86
70	The formulation of nanomedicines for treating tuberculosis. <i>Advanced Drug Delivery Reviews</i> , 2016, 102, 102-115.	6.6	83
71	Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 993-1002.	1.9	81
72	A comprehensive review of the neonatal Fc receptor and its application in drug delivery. , 2016, 161, 22-39.		80

#	ARTICLE	IF	CITATIONS
73	Chitosan-Coated Solid Lipid Nanoparticles for Insulin Delivery. <i>Methods in Enzymology</i> , 2012, 508, 295-314.	0.4	78
74	Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2011, 3, 389-399.	3.3	77
75	Hydrolyzed Galactomannan-Modified Nanoparticles and Flower-Like Polymeric Micelles for the Active Targeting of Rifampicin to Macrophages. <i>Journal of Biomedical Nanotechnology</i> , 2013, 9, 1076-1087.	0.5	77
76	Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system. <i>Biomaterials</i> , 2015, 68, 9-20.	5.7	77
77	Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine. <i>Pharmaceutical Research</i> , 2012, 29, 1468-1484.	1.7	74
78	<i>In Vitro</i> and <i>Ex Vivo</i> Evaluation of Polymeric Nanoparticles for Vaginal and Rectal Delivery of the Anti-HIV Drug Dapivirine. <i>Molecular Pharmaceutics</i> , 2013, 10, 2793-2807.	2.3	74
79	Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis. <i>Drug Delivery</i> , 2015, 22, 885-893.	2.5	74
80	Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides. <i>Peptides</i> , 2018, 101, 112-123.	1.2	71
81	Performance of an <i>in vitro</i> mucoadhesion testing method for vaginal semisolids: Influence of different testing conditions and instrumental parameters. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 622-632.	2.0	67
82	The role of mucus in cell-based models used to screen mucosal drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2018, 124, 50-63.	6.6	67
83	Interactions of Microbicide Nanoparticles with a Simulated Vaginal Fluid. <i>Molecular Pharmaceutics</i> , 2012, 9, 3347-3356.	2.3	65
84	Dissecting stromal-epithelial interactions in a 3D <i>in vitro</i> cellularized intestinal model for permeability studies. <i>Biomaterials</i> , 2015, 56, 36-45.	5.7	65
85	Novel amphiphilic chitosan micelles as carriers for hydrophobic anticancer drugs. <i>Materials Science and Engineering C</i> , 2020, 112, 110920.	3.8	65
86	Biodistribution and Pharmacokinetics of Dapivirine-Loaded Nanoparticles after Vaginal Delivery in Mice. <i>Pharmaceutical Research</i> , 2014, 31, 1834-1845.	1.7	64
87	Coffee silverskin: A possible valuable cosmetic ingredient. <i>Pharmaceutical Biology</i> , 2015, 53, 386-394.	1.3	64
88	Development and <i>in vivo</i> safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system. <i>Acta Biomaterialia</i> , 2016, 44, 332-340.	4.1	63
89	Combination of PLGA nanoparticles with mucoadhesive guar-gum films for buccal delivery of antihypertensive peptide. <i>International Journal of Pharmaceutics</i> , 2018, 547, 593-601.	2.6	63
90	Nanocarriers for pulmonary administration of peptides and therapeutic proteins. <i>Nanomedicine</i> , 2011, 6, 123-141.	1.7	62

#	ARTICLE	IF	CITATIONS
91	Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides. <i>Acta Biomaterialia</i> , 2015, 18, 77-87.	4.1	62
92	Solid Lipid Nanoparticles: A Potential Multifunctional Approach towards Rheumatoid Arthritis Theranostics. <i>Molecules</i> , 2015, 20, 11103-11118.	1.7	61
93	Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 138, 111-124.	2.0	60
94	Medicago spp. extracts as promising ingredients for skin care products. <i>Industrial Crops and Products</i> , 2013, 49, 634-644.	2.5	59
95	Insights on in vitro models for safety and toxicity assessment of cosmetic ingredients. <i>International Journal of Pharmaceutics</i> , 2017, 519, 178-185.	2.6	59
96	Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 653-663.	1.9	59
97	Rheological Properties of Vaginal Hydrophilic Polymer Gels. <i>Current Drug Delivery</i> , 2009, 6, 83-92.	0.8	58
98	Evaluation of radical scavenging activity, intestinal cell viability and antifungal activity of Brazilian propolis by-product. <i>Food Research International</i> , 2018, 105, 537-547.	2.9	57
99	Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals. <i>Progress in Materials Science</i> , 2017, 89, 306-344.	16.0	56
100	Chitosan Formulations as Carriers for Therapeutic Proteins. <i>Current Drug Discovery Technologies</i> , 2011, 8, 157-172.	0.6	55
101	Mad2 Checkpoint Gene Silencing Using Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles in Non-Small Cell Lung Cancer Model. <i>Molecular Pharmaceutics</i> , 2014, 11, 3515-3527.	2.3	55
102	Engineered Multifunctional Albumin-Decorated Porous Silicon Nanoparticles for FcRn Translocation of Insulin. <i>Small</i> , 2018, 14, e1800462.	5.2	53
103	Local Treatment of Vulvovaginal Candidosis. <i>Drugs</i> , 2008, 68, 1787-1802.	4.9	52
104	Antibodies and associates: Partners in targeted drug delivery. , 2017, 177, 129-145.		52
105	Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models. <i>Nanomedicine</i> , 2016, 11, 767-781.	1.7	51
106	Strategies for the enhanced intracellular delivery of nanomaterials. <i>Drug Discovery Today</i> , 2018, 23, 944-959.	3.2	49
107	Nanomedicine in the development of anti-HIV microbicides. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 57-75.	6.6	48
108	Burden of cancer in the Eastern Mediterranean Region, 2005–2015: findings from the Global Burden of Disease 2015 Study. <i>International Journal of Public Health</i> , 2018, 63, 151-164.	1.0	48

#	ARTICLE	IF	CITATIONS
109	Triple co-culture of human alveolar epithelium, endothelium and macrophages for studying the interaction of nanocarriers with the air-blood barrier. <i>Acta Biomaterialia</i> , 2019, 91, 235-247.	4.1	48
110	Zein nanoparticles as low-cost, safe, and effective carriers to improve the oral bioavailability of resveratrol. <i>Drug Delivery and Translational Research</i> , 2020, 10, 826-837.	3.0	48
111	Facts and Figures on Materials Science and Nanotechnology Progress and Investment. <i>ACS Nano</i> , 2021, 15, 15940-15952.	7.3	48
112	Microfluidic Nanoassembly of Bioengineered Chitosan-Modified FcRn-Targeted Porous Silicon Nanoparticles @ Hypromellose Acetate Succinate for Oral Delivery of Antidiabetic Peptides. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 44354-44367.	4.0	47
113	Development and Characterization of Chitosan Microparticles-in-Films for Buccal Delivery of Bioactive Peptides. <i>Pharmaceuticals</i> , 2019, 12, 32.	1.7	47
114	Mucoadhesive nanostructured polyelectrolytes complexes modulate the intestinal permeability of methotrexate. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 111, 73-82.	1.9	45
115	Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application. <i>International Journal of Nanomedicine</i> , 2014, 9, 4911.	3.3	44
116	Characterization of Commercially Available Vaginal Lubricants: A Safety Perspective. <i>Pharmaceutics</i> , 2014, 6, 530-542.	2.0	44
117	Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model. <i>Journal of Controlled Release</i> , 2016, 232, 113-119.	4.8	44
118	Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. <i>International Journal of Nanomedicine</i> , 2014, 9, 1757.	3.3	43
119	The potential of HIV-1 nanotherapeutics: from <i>in vitro</i> studies to clinical trials. <i>Nanomedicine</i> , 2015, 10, 3597-3609.	1.7	43
120	Assessing the physical-chemical properties and stability of dapivirine-loaded polymeric nanoparticles. <i>International Journal of Pharmaceutics</i> , 2013, 456, 307-314.	2.6	42
121	Gellan Gum/Pectin Beads Are Safe and Efficient for the Targeted Colonic Delivery of Resveratrol. <i>Polymers</i> , 2018, 10, 50.	2.0	42
122	Chitosan-Grafted Copolymers and Chitosan-Ligand Conjugates as Matrices for Pulmonary Drug Delivery. <i>International Journal of Carbohydrate Chemistry</i> , 2011, 2011, 1-14.	1.5	41
123	Synthesis and characterization of non-toxic and thermo-sensitive poly( N ) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 187 Td (-isopropyl) Carbohydrate Polymers, 2016, 154, 77-85.	5.1	40
124	Chemical modification of drug molecules as strategy to reduce interactions with mucus. <i>Advanced Drug Delivery Reviews</i> , 2018, 124, 98-106.	6.6	40
125	Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 138, 3-10.	2.0	40
126	Oral Delivery of Glucagon-like Peptide-1 and Analogs: Alternatives for Diabetes Control?. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 1486-1497.	1.3	39



#	ARTICLE	IF	CITATIONS
127	Formulation and delivery of anti-HIV rectal microbicides: Advances and challenges. <i>Journal of Controlled Release</i> , 2014, 194, 278-294.	4.8	39
128	Biological assessment of self-assembled polymeric micelles for pulmonary administration of insulin. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1621-1631.	1.7	39
129	Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier " from Targeting to Safe Administration. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 107-119.	2.1	39
130	Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6. <i>Acta Biomaterialia</i> , 2018, 81, 208-218.	4.1	39
131	Molecular and cellular cues governing nanomaterial"mucosae interactions: from nanomedicine to nanotoxicology. <i>Chemical Society Reviews</i> , 2020, 49, 5058-5100.	18.7	39
132	Safety and toxicity concerns of orally delivered nanoparticles as drug carriers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 381-393.	1.5	38
133	Synthesis and characterization of 3,6-O,O " dimyristoyl chitosan micelles for oral delivery of paclitaxel. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 152, 220-228.	2.5	38
134	Zein-casein-lysine multicomposite nanoparticles are effective in modulate the intestinal permeability of ferulic acid. <i>International Journal of Biological Macromolecules</i> , 2019, 138, 244-251.	3.6	38
135	Study of the isoflavone content of different extracts of <i>Medicago</i> spp. as potential active ingredient. <i>Industrial Crops and Products</i> , 2014, 57, 110-115.	2.5	37
136	PEGylated PLGA Nanoparticles As a Smart Carrier to Increase the Cellular Uptake of a Coumarin-Based Monoamine Oxidase B Inhibitor. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 39557-39569.	4.0	37
137	Synthesis and characterization of chitosan-grafted-polycaprolactone micelles for modulate intestinal paclitaxel delivery. <i>Drug Delivery and Translational Research</i> , 2018, 8, 387-397.	3.0	36
138	Development and characterization of lipid-polymeric nanoparticles for oral insulin delivery. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 213-222.	2.4	35
139	Bioadhesive polymeric nanoparticles as strategy to improve the treatment of yeast infections in oral cavity: in-vitro and ex-vivo studies. <i>European Polymer Journal</i> , 2018, 104, 19-31.	2.6	35
140	Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo. <i>Journal of Controlled Release</i> , 2021, 331, 198-212.	4.8	35
141	p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer. <i>Journal of Controlled Release</i> , 2021, 337, 329-342.	4.8	35
142	Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 52, 167-172.	1.4	34
143	Measuring the emulsification dynamics and stability of self-emulsifying drug delivery systems. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 123, 1-8.	2.0	34
144	Design, fabrication and characterisation of drug-loaded vaginal films: State-of-the-art. <i>Journal of Controlled Release</i> , 2020, 327, 477-499.	4.8	34

#	ARTICLE	IF	CITATIONS
145	Application of Coffee Silverskin in cosmetic formulations: physical/antioxidant stability studies and cytotoxicity effects. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 99-106.	0.9	33
146	Rational Development of Liposomal Hydrogels: A Strategy for Topical Vaginal Antiretroviral Drug Delivery in the Context of HIV Prevention. <i>Pharmaceutics</i> , 2019, 11, 485.	2.0	33
147	Incorporation of beads into oral films for buccal and oral delivery of bioactive molecules. <i>Carbohydrate Polymers</i> , 2018, 194, 411-421.	5.1	32
148	Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 34942-34953.	4.0	32
149	Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges. <i>Nanomedicine</i> , 2019, 14, 2631-2644.	1.7	32
150	Multicomponent self nano emulsifying delivery systems of resveratrol with enhanced pharmacokinetics profile. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 137, 105011.	1.9	30
151	Design and statistical modeling of mannose-decorated dapson-containing nanoparticles as a strategy of targeting intestinal M-cells. <i>International Journal of Nanomedicine</i> , 2016, 11, 2601.	3.3	29
152	Elucidation of the impact of cell culture conditions of Caco-2 cell monolayer on barrier integrity and intestinal permeability. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 119, 137-141.	2.0	29
153	Women's experiences, preferences and perceptions regarding vaginal products: Results from a cross-sectional web-based survey in Portugal. <i>European Journal of Contraception and Reproductive Health Care</i> , 2015, 20, 259-271.	0.6	28
154	The biopharmaceutical classification system of excipients. <i>Therapeutic Delivery</i> , 2017, 8, 65-78.	1.2	27
155	The role of non-endothelial cells on the penetration of nanoparticles through the blood brain barrier. <i>Progress in Neurobiology</i> , 2017, 159, 39-49.	2.8	27
156	Lipid nanocarriers loaded with natural compounds: Potential new therapies for age related neurodegenerative diseases?. <i>Progress in Neurobiology</i> , 2018, 168, 21-41.	2.8	27
157	&lt;p&gt;Delivering amoxicillin at the infection site &ndash; a rational design through lipid nanoparticles&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 2781-2795.	3.3	27
158	Clotrimazole-loaded N-(2-hydroxy)-propyl-3-trimethylammonium, O-palmitoyl chitosan nanoparticles for topical treatment of vulvovaginal candidiasis. <i>Acta Biomaterialia</i> , 2021, 125, 312-321.	4.1	27
159	Antioxidants in the Prevention and Treatment of Diabetic Retinopathy â€œ A Review. <i>Journal of Diabetes &amp; Metabolism</i> , 2010, 01, .	0.2	27
160	Foamability of Detergent Solutions Prepared with Different Types of Surfactants and Waters. <i>Journal of Surfactants and Detergents</i> , 2008, 11, 275-278.	1.0	26
161	Impact of in Vitro Gastrointestinal Digestion and Transepithelial Transport on Antioxidant and ACE-Inhibitory Activities of Brewerâ€™s Spent Yeast Autolysate. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 7335-7341.	2.4	26
162	<i>In vitro</i> Mâ€™like cells genesis through a tissueâ€™engineered tripleâ€™culture intestinal model. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2016, 104, 782-788.	1.6	26

#	ARTICLE	IF	CITATIONS
163	Carcinoembryonic antigen-targeted nanoparticles potentiate the delivery of anticancer drugs to colorectal cancer cells. <i>International Journal of Pharmaceutics</i> , 2018, 549, 397-403.	2.6	26
164	Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems. <i>Pharmaceutics</i> , 2019, 11, 145.	2.0	26
165	Solid state formulations composed by amphiphilic polymers for delivery of proteins: characterization and stability. <i>International Journal of Pharmaceutics</i> , 2015, 486, 195-206.	2.6	25
166	PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 119-125.	1.9	25
167	Surface modification with polyethylene glycol enhances colorectal distribution and retention of nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 130, 200-206.	2.0	25
168	Antioxidant and Anti-Inflammatory Properties of Cherry Extract: Nanosystems-Based Strategies to Improve Endothelial Function and Intestinal Absorption. <i>Foods</i> , 2020, 9, 207.	1.9	24
169	Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 20-32.	6.6	23
170	Rectal administration of nanosystems: from drug delivery to diagnostics. <i>Materials Today Chemistry</i> , 2018, 10, 128-141.	1.7	23
171	Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. <i>Bioactive Materials</i> , 2022, 9, 299-315.	8.6	23
172	Pharmacological and toxicological assessment of innovative self-assembled polymeric micelles as powders for insulin pulmonary delivery. <i>Nanomedicine</i> , 2016, 11, 2305-2317.	1.7	22
173	Self-aggregates of 3,6-O, O <sup>TM</sup> -dimyristoylchitosan derivative are effective in enhancing the solubility and intestinal permeability of camptothecin. <i>Carbohydrate Polymers</i> , 2017, 177, 178-186.	5.1	21
174	Stem cells as vehicles and targets of nanoparticles. <i>Drug Discovery Today</i> , 2018, 23, 1071-1078.	3.2	21
175	Polymeric Electrospun Fibrous Dressings for Topical Co-delivery of Acyclovir and Omega-3 Fatty Acids. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 390.	2.0	20
176	Chitosan and Chitosan Derivatives for Biological Applications: Chemistry and Functionalization. <i>International Journal of Carbohydrate Chemistry</i> , 2011, 2011, 1-1.	1.5	19
177	Development and Validation Method for Simultaneous Quantification of Phenolic Compounds in Natural Extracts and Nanosystems. <i>Phytochemical Analysis</i> , 2013, 24, 638-644.	1.2	19
178	Vaginal suppositories containing <i>Lactobacillus acidophilus</i> : development and characterization. <i>Drug Development and Industrial Pharmacy</i> , 2015, 41, 1518-1525.	0.9	19
179	N-(2-Hydroxy)-propyl-3-trimethylammonium, O-Myristoyl Chitosan Enhances the Solubility and Intestinal Permeability of Anticancer Curcumin. <i>Pharmaceutics</i> , 2018, 10, 245.	2.0	19
180	The effect of freeze-drying on mucoadhesion and transport of acrylated chitosan nanoparticles. <i>International Journal of Pharmaceutics</i> , 2020, 573, 118739.	2.6	19

#	ARTICLE	IF	CITATIONS
181	Development of pH-sensitive vaginal films based on methacrylate copolymers for topical HIV-1 pre-exposure prophylaxis. <i>Acta Biomaterialia</i> , 2021, 121, 316-327.	4.1	19
182	Combinatorial-Designed Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles for Encapsulation and Delivery of Lipid-Modified Platinum Derivatives in Wild-Type and Resistant Non-Small-Cell Lung Cancer Cells. <i>Molecular Pharmaceutics</i> , 2015, 12, 4466-4477.	2.3	18
183	Cell-based in vitro models for intestinal permeability studies. , 2016, , 57-81.		18
184	Targeted microbicides for preventing sexual HIV transmission. <i>Journal of Controlled Release</i> , 2017, 266, 119-128.	4.8	18
185	Women-specific routes of administration for drugs: A critical overview. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113865.	6.6	18
186	Vaginal Drug Delivery. , 0, , 809-878.		17
187	Antifungal activity of a gel containing <i>Thymus vulgaris</i> essential oil against <i>Candida</i> species commonly involved in vulvovaginal candidosis. <i>Pharmaceutical Biology</i> , 2009, 47, 151-153.	1.3	17
188	Prediction of the enhanced insulin absorption across a triple co-cultured intestinal model using mucus penetrating PLGA nanoparticles. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119516.	2.6	17
189	Nanosystem formulations for rectal microbicides: a call for more research. <i>Therapeutic Delivery</i> , 2012, 3, 1-4.	1.2	16
190	Technological strategies to overcome the mucus barrier in mucosal drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2018, 124, 1-2.	6.6	16
191	Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 136, 120-125.	1.4	15
192	Colorectal distribution and retention of polymeric nanoparticles following incorporation into a thermosensitive enema. <i>Biomaterials Science</i> , 2019, 7, 3801-3811.	2.6	15
193	Micelle-based Systems for Pulmonary Drug Delivery and Targeting. <i>Drug Delivery Letters</i> , 2011, 1, 171-185.	0.2	15
194	Impact of the in vitro gastrointestinal passage of biopolymer-based nanoparticles on insulin absorption. <i>RSC Advances</i> , 2016, 6, 20155-20165.	1.7	14
195	Antiretroviral drug-loaded nanoparticles-in-films: a new option for developing vaginal microbicides?. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 449-452.	2.4	14
196	Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990–2015: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 123-136.	1.0	13
197	Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113778.	6.6	13
198	Development of a microparticulate system containing Brazilian propolis by-product and gelatine for ascorbic acid delivery: evaluation of intestinal cell viability and radical scavenging activity. <i>Food and Function</i> , 2018, 9, 4194-4206.	2.1	12

#	ARTICLE	IF	CITATIONS
199	Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2021, 334, 453-462.	4.8	12
200	Development and validation of a HPLC method for the assay of dapivirine in cell-based and tissue permeability experiments. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 911, 76-83.	1.2	11
201	What do Portuguese Women Prefer Regarding Vaginal Products? Results from a Cross-Sectional Web-Based Survey. <i>Pharmaceutics</i> , 2014, 6, 543-556.	2.0	11
202	Antimicrobial properties of rosin acids-loaded nanoparticles against antibiotic-sensitive and antibiotic-resistant foodborne pathogens. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 414-422.	1.9	11
203	Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug. <i>International Journal of Pharmaceutics</i> , 2019, 557, 36-42.	2.6	11
204	Nanotechnologies for early diagnosis, in situ disease monitoring, and prevention. , 2018, , 1-92.		10
205	Design and characterization of an organogel system containing ascorbic acid microparticles produced with propolis by-product. <i>Pharmaceutical Development and Technology</i> , 2020, 25, 54-67.	1.1	10
206	Modelling protein therapeutic co-formulation and co-delivery with PLGA nanoparticles continuously manufactured by microfluidics. <i>Reaction Chemistry and Engineering</i> , 2020, 5, 308-319.	1.9	10
207	Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances. <i>Pharmaceutics</i> , 2021, 13, 1294.	2.0	9
208	Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 609-619.	0.9	9
209	Chitosan-Based Nanoparticles as Delivery Systems of Therapeutic Proteins. <i>Methods in Molecular Biology</i> , 2012, 899, 471-487.	0.4	8
210	Vaginal drug administration in the hospital setting. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 254-259.	0.5	7
211	A Mouse Intra-Intestinal Infusion Model and its Application to the Study of Nanoparticle Distribution. <i>Frontiers in Physiology</i> , 2016, 7, 579.	1.3	7
212	Influence of Plasticizers on the pH-Dependent Drug Release and Cellular Interactions of Hydroxypropyl Methylcellulose/Zein Vaginal Anti-HIV Films Containing Tenofovir. <i>Biomacromolecules</i> , 2021, 22, 938-948.	2.6	7
213	Preparation of Polyelectrolyte Nanocomplexes Containing Recombinant Human Hepatocyte Growth Factor as Potential Oral Carriers for Liver Regeneration. <i>Methods in Molecular Biology</i> , 2012, 811, 113-125.	0.4	7
214	Vaginal multipurpose prevention technologies: promising approaches for enhancing women's sexual and reproductive health. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 379-393.	2.4	7
215	Development and validation of a new one step Multiplex-PCR assay for the detection of ten <i>Lactobacillus</i> species. <i>Anaerobe</i> , 2019, 59, 192-200.	1.0	6
216	Advanced polymeric nanotechnology to augment therapeutic delivery and disease diagnosis. <i>Nanomedicine</i> , 2020, 15, 2287-2309.	1.7	6

#	ARTICLE	IF	CITATIONS
217	<i>In vitro</i> intestinal absorption of amino acid mixtures extracted from codfish (<i>Gadus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 27-33.	1.3	4
218	Editorial: Biomedical Engineering Approaches for HIV/AIDS Prophylaxis, Diagnostics and Therapy. Advanced Drug Delivery Reviews, 2016, 103, 1-4.	6.6	4
219	Novel Approaches for the Delivery of Anti-HIV Drugs&€”What Is New?. Pharmaceutics, 2019, 11, 554.	2.0	4
220	Mucus-producing 3D cell culture models. Advanced Drug Delivery Reviews, 2021, 178, 113993.	6.6	4
221	Nanotechnology Inclusion in Pharmaceutical Sciences Education in Portugal. American Journal of Pharmaceutical Education, 2018, 82, 6403.	0.7	3
222	3D Model Replicating the Intestinal Function to Evaluate Drug Permeability. Methods in Molecular Biology, 2018, 1817, 107-113.	0.4	3
223	Bioactive Protein Hydrolysate Obtained from Canned Sardine and Brewing By-products: Impact of Gastrointestinal Digestion and Transepithelial Absorption. Waste and Biomass Valorization, 2021, 12, 1281-1292.	1.8	3
224	Vaginal Delivery of Biopharmaceuticals. , 2014, , 261-280.		3
225	Misoprostol and pregnancy termination. Lancet, The, 2007, 370, 1824.	6.3	2
226	Vaginal microbicides: the importance of effective distribution, retention and coating of the mucosa. Aids, 2008, 22, 908-909.	1.0	2
227	Tissue-based in vitro and ex&Aacute;vivo&Aacute;models for vaginal permeability studies. , 2016, , 273-308.		2
228	Establishment of a multilayered 3D cellular model of the retinal-blood barrier. International Journal of Pharmaceutics, 2019, 572, 118811.	2.6	2
229	Pulmonary Delivery of Biopharmaceuticals. , 2014, , 169-195.		2
230	Nanoparticulate targeted drug delivery using peptides and proteins. , 2012, , 236-301.		1
231	Quality Control and Good Manufacturing Practice (GMP) for Chitosan-Based Biopharmaceutical Products. , 2012, , 503-524.		1
232	Production and Characterization of Anti-CCR5 siRNA-Loaded Polycaprolactone Nanoparticles for Topical Pre-exposure Prophylaxis. Methods in Molecular Biology, 2021, 2282, 403-416.	0.4	1
233	A scale-up strategy for the synthesis of chitosan derivatives used in micellar nanomedicines. International Journal of Pharmaceutics, 2021, 609, 121151.	2.6	1
234	MPTHub: An Open-Source Software for Characterizing the Transport of Particles in Biorelevant Media. Nanomaterials, 2022, 12, 1899.	1.9	1

#	ARTICLE	IF	CITATIONS
235	Fourteen-day Safety of Daily Vaginal Administration of Dapivirine-loaded Nanoparticles in a Mouse Model. AIDS Research and Human Retroviruses, 2014, 30, A149-A149.	0.5	0